Across TCGA pan-cancer cohorts, GUSBP8 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GUSBP8’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where GUSBP8 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GUSBP8 is over-expressed in tumor.
PRAD are the cancer types where GUSBP8 tumor–normal differential expression is most reproducible.